Robert Mittendorff, MD, MBA (@doctorrem) profile picture

Venture Capitalist, Physician, Biomedical Engineer. @Harvard MD&MBA, @Stanford EM, MA @KCLSecurity, BS BME/EE @JohnsHopkins. Personal account - views mine.

San Francisco, CA
Joined August 2012
Photo by Robert Mittendorff, MD, MBA (@doctorrem)Photo by Robert Mittendorff, MD, MBA (@doctorrem)Photo by Robert Mittendorff, MD, MBA (@doctorrem)Photo by Robert Mittendorff, MD, MBA (@doctorrem)Photo by Robert Mittendorff, MD, MBA (@doctorrem)Photo by Robert Mittendorff, MD, MBA (@doctorrem)Photo by Robert Mittendorff, MD, MBA (@doctorrem)Photo by Robert Mittendorff, MD, MBA (@doctorrem)Photo by Robert Mittendorff, MD, MBA (@doctorrem)Photo by Robert Mittendorff, MD, MBA (@doctorrem)
Robert Mittendorff, MD, MBA retweeted
For readers interested in GLP-1 receptor-based therapies for diabetes, obesity and beyond, here's a comprehensive review nature.com/articles/s41573-0… rdcu.be/WP9YfmRxmena
1
50
3
150
10,665
Robert Mittendorff, MD, MBA retweeted
Kevin co-chairs our scientific advisory board Kevin is at @MIT and one of the smartest people in the world on issues of engineered pathogens Kevin's tweets are worth your time
Russia's five-hospital quarantine, FSB involvement, and reported hazmat use in response to the death of a single researcher at a weapons-lineage Irkutsk lab are inconsistent with a lab-acquired plague infection, which would have been treated with prophylactic antibiotics. 1/4
93
1,486
43
9,603
1,417,080
On the private side, valuations of the AI drug discovery companies are insane. Especially for the many companies with no scalable pipeline. 2001 all over again. Interesting interview via @chrissyfarr
A $2.1 *billion* Series B. Isomorphic Labs' round helped push biopharma to the top of healthcare venture funding in H1 2026, with $12.6B raised. And it raises a bigger question: with no independent pipeline of its own, is an AI drug discovery company a tech company or a life science company? Was great to have Megan Scheffel back on Rounds with Stephanie and I to break down the latest @SiliconVlyBank report, and what these mega-rounds mean as the lines between tech and bio blur and well-funded companies look to make their next move. Link to the full episode and report in comments ↓
3
4
53
5,641
Robert Mittendorff, MD, MBA retweeted
To avoid stating the obvious: the goal of virtual cells isn’t to achieve great perturbation prediction. Perturbation prediction is a means, not the end. The real objective is to build a foundation model that powers downstream drug discovery, from target identification and mechanism-of-action inference to toxicity prediction, biomarker discovery, and therapeutic design. Let’s not optimize for the proxy instead of the mission.
10
12
4
121
40,999
Robert Mittendorff, MD, MBA retweeted
1/📢 New preprint! Do you actually need a biology-specific foundation model to predict how cells respond to perturbations? Surprising answer: a general-purpose tabular model - never trained on a single cell - matches or beats the specialists! 📄 doi.org/10.64898/2026.06.28.… @biohub
4
44
7
250
56,364
Robert Mittendorff, MD, MBA retweeted
First true AI drug in a phase 3 trial, this is exciting. Insilico's rentosertib is the first end-to-end generative-AI-discovered drug. Its AI models helped select a novel TNIK target for IPF and designed the molecule, reaching a preclinical candidate in ~18 months with <80 compounds synthesized, vs. the usual 2.5–4 yrs and thousands of molecules made. First-in-human by Feb 2022, positive Phase 1 by Jan 2023, Phase 2 that same year, now heading toward Phase III. Roughly half the industry's typical timeline to the clinic. AI drug discovery, getting there.
Hello, my dear friends, we have some breaking news today! Our rentosertib (novel target that has never been in clinical trials before we picked it using AI, novel molecule designed using true generative AI with the published broadly used AI platform, targeting fibrosis and biology of aging) entered Phase III trial in Idiopathic Pulmonary Fibrosis. This is a major milestone in the life of every drug hunter - the ultimate test. To my knowledge, in our AI drug discovery industry, no other company took the drug for a novel target with a novel molecule into Phase III before so it is a big milestone for the entire industry. Of course, at Insilico we are no longer dependent on this program - we have 13 INDs and many clinical trials are ongoing internally and run by partners. But this program is very special as we also demonstrated the senomorphic properties of this drug and built the entire pipeline of molecules around this target. Please Wish Me Luck! Luck is the most important superpower in everything we do and if we succeed with this program and also demonstrate the antiaging effect - all of us will benefit. Godspeed, my friends and thanks to everyone who helped us along the way!
1
5
61
9,023
Robert Mittendorff, MD, MBA retweeted
How much time do FDA expedited designations save? Accelerated approval and Breakthrough status save a statistically significant amount of time. But Fast track does not Investors should keep this in mind #learnbiotechinvesting #biotech #investing #BiotechPrometheus
3
9
1,836
Robert Mittendorff, MD, MBA retweeted
We spoke to six lawyers in health tech about California targeting the friendly PC model with the Carbon Health settlement. Investors are also worried. Here’s the breakdown and analysis. Anyone in care delivery should be following. 👇 secondopinion.media/p/califo…
2
5
21
5,489
Robert Mittendorff, MD, MBA retweeted
For years now we have been hearing that the public no longer trusts science. But the data actually tells a very different story. Across dozens of countries, scientists remain among the most trusted professions.
16
59
5
223
5,773
Robert Mittendorff, MD, MBA retweeted
David Friedberg says Anthropic asked big pharma for their data and nearly everyone said no "There's been an effort by Anthropic to sign up life sciences companies to contribute to a new life sciences focused model. They're approaching these large companies with large proprietary data sets and saying, if you share your data, we will give you early access, some sort of proprietary value. Sign this NDA and you can participate with us." "I think nearly everyone I've spoken with has woken up to the fact that they are trying to commoditize everyone's business. If all of the tens of billions of dollars you have invested in experiments and product development, and you've generated all of this proprietary data along the way, that data is a true asset of your organization. It's an asset that you've spent billions of dollars developing." "And by handing it over to a model company to then combine with other people's data, you are commoditizing the one core differentiation that you have. And so everyone is largely saying no." "I think what everyone's realizing is they're better off developing their own weights and their own models using either an open source basis or there might be some intermediary business model that evolves."
53
174
54
1,310
288,893
Robert Mittendorff, MD, MBA retweeted
Adding another one to the collection... Out now: a new piece analyzing the explosion of deal flow of China-US over the past few years, and whether it spells disaster for Western biotech.
A Reading Guide to Chinese Biotech Some friends and I visited China to learn about its biotech ecosystem. Beforehand, we assembled a list of 51 "high signal" books, podcasts, and articles to help us prepare. During the trip, we also asked people who *they* followed for their news on China, and then we added many of those names to this guide. Hopefully this will be a useful resource for folks who are planning to visit (which I recommend, especially if you work in drug development.)
2
8
2
108
24,653
Robert Mittendorff, MD, MBA retweeted
ARCH is excited to Co-lead the Series A and to join the Board of Oratomic, to build a fault-tolerant Quantum computer, one of the grand challenges for humans. The impact of quantum computing on biology, defense, AI and almost everywhere is hard to understate.
6
3
1
68
15,639
Robert Mittendorff, MD, MBA retweeted
If you were a research organization or a life sciences company, would you hand over your data to an AI company allowing them to combine it with others, monetize it, and commoditize your business?
David Friedberg says Anthropic asked big pharma for their data and nearly everyone said no "There's been an effort by Anthropic to sign up life sciences companies to contribute to a new life sciences focused model. They're approaching these large companies with large proprietary data sets and saying, if you share your data, we will give you early access, some sort of proprietary value. Sign this NDA and you can participate with us." "I think nearly everyone I've spoken with has woken up to the fact that they are trying to commoditize everyone's business. If all of the tens of billions of dollars you have invested in experiments and product development, and you've generated all of this proprietary data along the way, that data is a true asset of your organization. It's an asset that you've spent billions of dollars developing." "And by handing it over to a model company to then combine with other people's data, you are commoditizing the one core differentiation that you have. And so everyone is largely saying no." "I think what everyone's realizing is they're better off developing their own weights and their own models using either an open source basis or there might be some intermediary business model that evolves."
5
7
2
23
5,941
Robert Mittendorff, MD, MBA retweeted
Our paper in @Nature today 🥳 We tracked 6,438 mice from puberty to death and mapped the genetics of *when* you die, not just whether a gene associates with lifespan. nature.com/articles/s41586-0… 59 loci. Two decades of data. Thread 👇 #Longevity #Aging #Genetics #Healthspan
16
279
26
1,230
123,751
Robert Mittendorff, MD, MBA retweeted
The most promising longevity drug isn't a peptide or metformin. It's the Shingles vaccine. New data shows it slows biological aging and lowers systemic inflammation for 4+ years post-shot. We are seeing a 20% reduction in new dementia diagnoses and a 25% lower risk of stroke. Stop waiting for a magic pill. One is already on the shelf. – at New York, USA
🤖 Made with AI
218
899
73
4,066
307,558
Robert Mittendorff, MD, MBA retweeted
Today @OpenAI introduced ChatGPT for Clinicians, provided free for credentialed HCPs, and HealthBench Professional for benchmarking LLM medical task performance (Figure) openai.com/index/making-chat… cdn.openai.com/dd128428-0184…
33
202
15
693
107,306
Robert Mittendorff, MD, MBA retweeted
In Brief: China approves a brain implant that enables people with paralysis to move their hands — the world’s first approval of an invasive brain–computer interface for commercial use nature.com/articles/s41587-0…
1
12
1
31
4,032
Robert Mittendorff, MD, MBA retweeted
A former MD Anderson researcher in Houston was sentenced to jail after pleading guilty in a cancer data theft case and is expected to be deported. bit.ly/3Ns7lu2
19
187
30
447
43,529